Immunogenicity of Infanrix鈩?hexa administered at 3, 5 and 11 months of age

详细信息	查看全文 | 推荐本文 |

• 作者：Olivier Van Der Meeren^a ; ^{Olivier.x.Van-Der-Meeren@gskbio.com} ; Sherine Kuriyakose^b ; ^{Sherine.O.Kuriyakose@gsk.com} ; Devayani Kolhe^b ; ^{Devayani.A.Kolhe@gsk.com} ; Karin Hardt^a ; ^{karin.hardt@gskbio.com}
• 关键词：渭g/ml ; micrograms per millilitre ; ATP ; according to protocol ; CI ; confidence interval ; DTPa&ndash ; HBV&ndash ; IPV/Hib ; diphtheria&ndash ; tetanus&ndash ; acellular pertussis ; hepatitis B ; inactivated poliovirus and Haemophilus influenzae type b vaccine ; ELISA
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：5 April, 2012
• 卷：30
• 期：17
• 页码：2710-2714
• 文件大小：170 K

摘要

A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix鈩?hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11-12 months of age. One month after dose 2, between 96.3%and 100%of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7%against Hib and 鈮?9.0%were seropositive for each pertussis antigen. One month after the third dose, 98.9-100%of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7-52.9 fold after the third vaccine dose. No serious adverse events in DTPa-HBV-IPV/Hib recipients were vaccine related. Infanrix鈩?hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.